ovarian cancer

Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer
BioSpace
Mon, 07/13/20 - 12:15 pm
Genentech
Roche
clinical trials
Tecentriq
ovarian cancer
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Thu, 06/11/20 - 11:16 am
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval
Endpoints
Mon, 05/11/20 - 10:40 am
AstraZeneca
Merck
Lynparza
ovarian cancer
Go or no go? Oncology dominates upcoming decisions
EP Vantage
Fri, 05/1/20 - 11:09 am
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations
Endpoints
Wed, 04/29/20 - 10:45 pm
GSK
Zejula
Tesara
FDA
ovarian cancer
Epsilogen licenses first-in-class IgE ovarian cancer drug
Pharmaforum
Mon, 04/20/20 - 10:41 am
Epsilogen
ovarian cancer
Mov18
AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer
Fierce Biotech
Tue, 03/24/20 - 10:43 am
ovarian cancer
Carisma Therapeutics
CAR-M
CAR-T
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
BioPharma Dive
Thu, 03/12/20 - 12:58 pm
AstraZeneca
Merck
cediranib
ovarian cancer
clinical trials
Lynparza
FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer
BioSpace
Tue, 02/25/20 - 04:59 pm
GSK
Zejula
ovarian cancer
FDA
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
Mon, 01/13/20 - 11:49 pm
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Anixa delays CAR-T trial in bid to boost efficacy
Fierce Biotech
Fri, 12/13/19 - 11:00 am
Anixa Biosciences
ovarian cancer
CAR-T
FDA slaps a hold on an AML trial as Marker scraps a failing ovarian cancer program, sinking shares
Endpoints
Thu, 11/14/19 - 07:29 pm
Marker Therapeutics
AML
ovarian cancer
clinical trials
FDA
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
Thu, 10/24/19 - 10:08 am
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
Sat, 09/28/19 - 05:00 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Sat, 09/28/19 - 04:49 pm
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
ESMO 2019 preview – PARPs on parade
EP Vantage
Thu, 09/5/19 - 12:06 pm
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
Pharmaforum
Wed, 08/14/19 - 11:01 am
AstraZeneca
Merck
Lynparza
clinical trials
advanced ovarian cancer
ovarian cancer
Calquence
GSK drug helps ovarian cancer patients live longer in late-stage study
Yahoo/Reuters
Mon, 07/15/19 - 09:59 am
GSK
Zejula
ovarian cancer
clinical trials
GSK wins speedy FDA Zejula review in ovarian cancer niche
Fierce Pharma
Mon, 06/24/19 - 07:13 pm
GSK
FDA
Zejula
ovarian cancer
late-stage ovarian cancer
Tesaro
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
Yahoo/Reuters
Tue, 06/18/19 - 10:04 am
AstraZeneca
Lynparza
ovarian cancer
Europe

Pages